Filing summary
Entity mismatch: The request identifies Aleanna, Inc., but the supplied Form 10-Q is for Swiftmerge Acquisition Corp. This summary reflects the filing provided.
Business context and reporting period
Swiftmerge is a Cayman Islands blank-check company seeking a business combination; it had no operating business or operating revenue through June 30, 2023. This unaudited quarterly report covers the three and six months ended June 30, 2023, compared with the same 2022 periods.
Financial performance and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Formation and operating costs | 2023: $1.21 million; 2022: $0.36 million | 2023: $2.43 million; 2022: $0.78 million |
| Trust investment gain | 2023: $2.69 million; 2022: $0.30 million | 2023: $5.01 million; 2022: $0.32 million |
| Net income (loss) | 2023: $1.47 million; 2022: $(54,614) | 2023: $2.58 million; 2022: $(488,977) |
| Basic and diluted earnings (loss) per share | 2023: $0.06; 2022: approximately $0.00 loss | 2023: $0.10; 2022: $(0.02) |
At June 30, 2023, cash outside the Trust Account was $172,900, prepaid expenses were $280,039, Trust Account investments were $22.89 million, and total assets were $23.34 million. Current liabilities were $2.82 million. The balance sheet implies a working-capital deficit of $2.37 million; MD&A and the liquidity note state $2.17 million, while the risk-factor section states $2.37 million. Shareholders’ deficit was $2.27 million. The filing reports no long-term debt. A $200,000 Sponsor advance was outstanding at period-end.
Operating cash outflow for the six months was $489,014, compared with $296,972 in 2022. The $211.9 million of Trust Account withdrawals and corresponding redemption payments drove large investing and financing cash flows; these were not operating cash generation.
Material changes versus prior comparable period
- Net income replaced the prior-period loss, primarily because Trust Account investment gains increased substantially; operating costs also rose.
- In June 2023, shareholders approved extending the business-combination deadline to March 15, 2024. Holders redeemed 20,253,090 Class A shares for approximately $211.9 million, leaving 5,621,910 Class A shares outstanding and approximately $22.9 million in the Trust Account at quarter-end.
- The Sponsor converted 3,375,000 Class B founder shares into Class A shares following the June vote.
- The underwriter had waived its $7.875 million deferred underwriting commission in November 2022.
Outlook, risks and unusual items
- Management concluded that substantial doubt exists about Swiftmerge’s ability to continue as a going concern: its operating cash forecast did not cover obligations through March 15, 2024. Additional financing was not committed, and the company warned it may need to curtail operations or suspend transaction efforts if funding is unavailable.
- After quarter-end, on August 11, 2023, Swiftmerge agreed to combine with HDL Therapeutics, Inc. The announced transaction values HDL equity consideration at $400 million, payable in cash and shares valued at $10 per share, with up to 11 million additional earnout shares tied to share-price milestones. Closing remains subject to conditions and shareholder approval.
- HDL agreed to seek pre-closing financing, including $2.68 million through December 31, 2023 and up to an additional $3 million thereafter. Certain expense-related merger obligations depend on obtaining this financing or HDL’s ability to pay its obligations.
- On September 15, 2023, the Sponsor promissory note was formalized for up to $500,000; the $200,000 advance was converted into the note. It is non-interest-bearing and may be converted into warrants at the Sponsor’s option.
- Management disclosed ineffective disclosure controls due to a material weakness involving unbilled service-provider liabilities, the deferred underwriting fee, and interest income. The company said previously filed 2022 and first-quarter 2023 statements should no longer be relied upon and would be restated; it stated the changes do not affect cash.
- The company noted possible effects from the U.S. stock-repurchase excise tax and broad market uncertainty. Public warrants may expire worthless if no business combination is completed.
Most important facts to verify
- Confirm the issuer identity: the supplied filing is Swiftmerge Acquisition Corp., not Aleanna, Inc.
- Reconcile the working-capital deficit: $2.17 million in parts of the filing versus $2.37 million in the balance-sheet calculation and risk-factor disclosure.
- Check the status and terms of the HDL merger, required approvals, financing conditions, and any subsequent amendments or termination.
- Review the promised restatements, their final adjustments, and remediation of the disclosed material weakness.
- Verify available Sponsor financing and whether cash outside the Trust Account can fund costs through the extended deadline.